FDA Flags High-Risk Recall Of Insulet's Omnipod 5 Pods Over Insulin Delivery Concerns

The FDA has classified Insulet's Omnipod 5 insulin pump recall as its most serious type due to a defect causing potential insulin under-delivery. The flaw involves small tears in internal tubing that can lead to insulin leakage without triggering alarms, risking elevated blood glucose levels and potentially life-threatening diabetic ketoacidosis. The company reported 476 serious injuries with no deaths. Insulet shares fell 10.95% to a new 52-week low of $162.84.

04/29/2026, 2:30 PM • Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GoHealth Inc. - GOCO

Pomerantz LLP is investigating securities fraud claims against GoHealth Inc. and other companies following a May 1, 2025 Department of Justice false Claims Act complaint alleging illegal kickbacks to brokers between 2016 and 2021. GoHealth's stock fell 10.4% to $9.44 per share on the news.

04/21/2026, 4:59 PM • GlobeNewswire

This Biotech Stock Up Nearly 100% in a Year Has Drawn a New $20 Million Share Investment

Parkman Healthcare Partners established a new $20 million position in EyePoint Pharmaceuticals by purchasing 1.088 million shares in Q4 2025. EyePoint shares have surged 93% over the past year as the company advances DURAVYU, a sustained-release therapy for retinal diseases, with Phase 3 trial data expected mid-2026. Despite significant losses and development-stage operations, the company has sufficient cash runway into late 2027.

03/15/2026, 7:05 PM • The Motley Fool

Insulet Stock Hits 52-Week Low - Here's Why

Insulet Corp. (NASDAQ:PODD) shares fell to a 52-week low following the announcement of a voluntary Medical Device Correction for certain Omnipod 5 Pods. The manufacturing defect involves a small tear in internal tubing that delivers insulin, potentially causing under-delivery and serious health complications including diabetic ketoacidosis. The company has received 18 reports of serious adverse events. The affected pods represent approximately 1.5% of annual global production. Despite a Buy rating from analysts with a $356.64 price target, technical indicators show mixed momentum with the stock trading below key moving averages.

03/13/2026, 9:45 AM • Benzinga

Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market

The global health and wellness sector is projected to reach $6 trillion in annual consumer spending in 2026, driven by demand for functional products and stricter clean-label regulations. Five companies are capitalizing on this trend: Doseology Sciences launched caffeine-based energy pouches; Amneal Pharmaceuticals introduced a new brand identity and plans an Accessibility Index; Prestige Consumer Healthcare expanded its dry eye care portfolio; Viking Therapeutics advanced its obesity drug portfolio with Phase 3 trials; and Insulet expanded its automated insulin delivery system to the Middle East.

02/13/2026, 11:26 AM • Benzinga

BVI Appoints Jim Hollingshead as President & Chief Executive Officer

BVI announced the appointment of Jim Hollingshead as President & CEO, succeeding Shervin Korangy. Hollingshead brings over 20 years of medical device experience from leadership roles at Insulet and ResMed. BVI has expanded its ophthalmic portfolio with FDA approvals for premium IOLs and new surgical platforms, positioning itself as a challenger in the eye surgery market.

01/19/2026, 9:00 AM • GlobeNewswire

Insulet Peer Tandem Diabetes Underwhelming Earnings, Dull Outlook Drags Stock

Tandem Diabetes Care reported a Q2 loss of $0.78 per share, missed earnings estimates, and announced a voluntary medical device correction for t:slim X2 insulin pumps due to potential speaker-related issues affecting insulin delivery.

08/07/2025, 1:50 PM • Benzinga

Insulet Lifts Annual Forecast On Increased Adoption For Insulin Pump Omnipod 5

Insulet reported strong Q2 earnings, beating estimates with $649.1 million in revenue, and raised its full-year sales guidance to $2.57-$2.63 billion, driven by increased adoption of its Omnipod 5 insulin pump technology.

08/07/2025, 1:08 PM • Benzinga

Diabetes Care Devices Market Size Projects USD 76.44 Billion by 2034

The global diabetes care devices market is projected to grow from $33.58 billion in 2024 to $76.44 billion by 2034, driven by increasing diabetes cases, technological advancements, and rising awareness of diabetes management tools.

07/31/2025, 10:00 AM • GlobeNewswire

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential

Several healthcare and AI-driven companies are demonstrating significant potential in transforming medical technologies, offering innovative therapies and solutions across various medical domains like gene editing, telehealth, and precision medicine.

06/28/2025, 9:10 AM • The Motley Fool